近日，国家医保局发布通知，对65种药品的医保报销范围进行了调整。此次调整旨在优化医保基金使用效率，更好地保障参保人员的基本医疗需求。部分药品被新增纳入医保报销目录，涵盖肿瘤、罕见病、慢性病等治疗领域，有助于减轻患者用药负担；同时，也有部分药品因临床价值不高、价格虚高或已有更优替代品等原因，被调出或限制报销条件。值得注意的是，此次调整并非简单‘进’或‘出’，而是根据药品的安全性、有效性、经济性等多维度评估结果进行精细化管理。例如，某些高价抗癌药在谈判降价后被纳入报销，但限定用于特定适应症；而一些辅助用药则被严格限制使用场景，防止医保资金浪费。政策将于2024年正式实施，各地将根据国家统一部署逐步落实。专家建议患者及时关注本地医保政策变化，合理规划用药。总体来看，此次调整体现了医保制度从‘广覆盖’向‘精准保障’的转变，有助于推动医药行业高质量发展和患者获益双赢。
Recently, China’s National Healthcare Security Administration (NHSA) announced adjustments to the reimbursement scope of 65 drugs under the national health insurance scheme. The changes aim to optimize the use of medical insurance funds and better meet the essential healthcare needs of insured individuals. Some drugs—particularly those for cancer, rare diseases, and chronic conditions—have been newly added to the reimbursement list, helping reduce patients’ out-of-pocket medication costs. Conversely, other drugs have been removed or subjected to stricter reimbursement criteria due to limited clinical value, inflated pricing, or the availability of superior alternatives.Importantly, these adjustments are not simply binary inclusions or exclusions. Instead, they reflect a nuanced, evidence-based approach that evaluates each drug’s safety, efficacy, and cost-effectiveness. For instance, certain high-cost anticancer drugs were included after successful price negotiations but are restricted to specific approved indications. Meanwhile, some adjuvant medications now face tighter usage restrictions to prevent wasteful spending of insurance funds.The policy will take effect in 2024, with local authorities implementing it gradually according to national guidelines. Experts advise patients to stay informed about regional updates to plan their treatment accordingly. Overall, this revision marks a strategic shift in China’s health insurance system—from broad coverage toward precise, value-based protection—benefiting both public health and the sustainable development of the pharmaceutical industry.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/9984.html